США - англійська - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

Ізраїль - англійська - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - pentosan polysulfate sodium (unii: 914032762y) (pentosan polysulfate - unii:f59p8b75r4) - pentosan polysulfate sodium 100 mg - elmiron® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. elmiron® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arthropharm pty ltd - pentosan polysulfate sodium, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; sodium lauryl sulfate; silicon dioxide - indications as at 5 august 2021: elmiron is indicated for the treatment of interstitial cystitis. relief of symptoms in patients with interstitial cystitis may not be experienced until 6 to 8 weeks of therapy with elmiron. continuing long-term therapy is necessary for persistent relief of symptoms. relief of symptoms may not occur in all patients, and relapse is likely to occur gradually if treatment is discontinued, even after long periods of therapy.

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca (flight) co pty ltd - cobalt as cobaltous sulfate heptahydrate; copper present as copper sulfate pentahydrate; iron as ferric ammonium citrate, ferrous gluconate, ferr; manganese as manganese sulfate monohydrate - oral solution/suspension - cobalt as cobaltous sulfate heptahydrate mineral-cobalt active 0.2 mg/l; copper present as copper sulfate pentahydrate mineral-copper active 14.7 mg/l; iron as ferric ammonium citrate, ferrous gluconate, ferr mineral-iron active 16.0 g/l; manganese as manganese sulfate monohydrate mineral-manganese active 14.9 mg/l - nutrition & metabolism - dog - greyhound | horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | - iron supplement

США - англійська - NLM (National Library of Medicine)

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

США - англійська - NLM (National Library of Medicine)

contract pharmacy services-pa - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

США - англійська - NLM (National Library of Medicine)

blenheim pharmacal, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

США - англійська - NLM (National Library of Medicine)

state of florida doh central pharmacy - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

США - англійська - NLM (National Library of Medicine)

major pharmaceuticals - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona